GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vericel Corp (NAS:VCEL) » Definitions » Price-to-Free-Cash-Flow

Vericel (Vericel) Price-to-Free-Cash-Flow

: 276.83 (As of Today)
View and export this data going back to 1997. Start your Free Trial

As of today (2024-04-23), Vericel's share price is $45.40. Vericel's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.16. Hence, Vericel's Price-to-Free-Cash-Flow Ratio for today is 276.83.

The historical rank and industry rank for Vericel's Price-to-Free-Cash-Flow or its related term are showing as below:

VCEL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 68.68   Med: 120.32   Max: 317.2
Current: 276.68

During the past 13 years, Vericel's highest Price-to-Free-Cash-Flow Ratio was 317.20. The lowest was 68.68. And the median was 120.32.

VCEL's Price-to-Free-Cash-Flow is ranked worse than
89.62% of 212 companies
in the Biotechnology industry
Industry Median: 30.125 vs VCEL: 276.68

Vericel's Free Cash Flow per Share for the three months ended in Dec. 2023 was $0.05. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.16.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Vericel was -23.40% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -19.60% per year.

During the past 13 years, Vericel's highest 3-Year average Free Cash Flow per Share Growth Rate was 64.20% per year. The lowest was -19.60% per year. And the median was 17.65% per year.


Vericel Price-to-Free-Cash-Flow Historical Data

The historical data trend for Vericel's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vericel Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 97.72 86.37 123.08 217.13

Vericel Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 123.08 159.35 131.82 139.09 217.13

Competitive Comparison

For the Biotechnology subindustry, Vericel's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vericel Price-to-Free-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, Vericel's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Vericel's Price-to-Free-Cash-Flow falls into.



Vericel Price-to-Free-Cash-Flow Calculation

Vericel's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=45.40/0.164
=276.83

Vericel's Share Price of today is $45.40.
Vericel's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.16.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Vericel  (NAS:VCEL) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Vericel Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Vericel's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Vericel (Vericel) Business Description

Traded in Other Exchanges
Address
64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
Executives
Dominick Colangelo director, officer: President and CEO 1000 WINTER ST., SUITE 2200, WALTHAM MA 02451
Zerbe Robert L Md director
Paul K Wotton director C/O ANTARES PHARMA, INC., 707 EAGLEVIEW BOULEVARD, SUITE 414, EXTON PA 19341
Sean C. Flynn officer: SVP, General Counsel C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Michael Halpin officer: Chief Operating Officer C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Jonathan Mark Hopper officer: Chief Medical Officer 64 SIDNEY STREET, CAMBRIDGE MA 02139
Jonathan Siegal officer: Principal Accounting Officer C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Lisa Wright director C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Mara Joseph Anthony Jr officer: Chief Financial Officer C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Sandra Pennell officer: VP and Corporate Controller C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Gerard J Michel officer: CFO & VP , Corp. Development 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Daniel Orlando officer: Chief Operating Officer P.O. BOX 376, ANN ARBOR MI 48105
Alan L Rubino director PO BOX 376, LOBBY L., ANN ARBOR MI 48105
Consonance Capital Management Lp 10 percent owner 1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK NY 10019